...
机译:CD34 +细胞剂量对强度调理方案造血干细胞移植降低的影响
Section of Medical Oncology and HematologyUniversity of TorontoON Canada;
Department of BiostatisticsUniversity Health NetworkToronto ON Canada;
Section of Medical Oncology and HematologyUniversity of TorontoON Canada;
Section of Medical Oncology and HematologyUniversity of TorontoON Canada;
Section of Medical Oncology and HematologyUniversity of TorontoON Canada;
Section of Medical Oncology and HematologyUniversity of TorontoON Canada;
Section of Medical Oncology and HematologyUniversity of TorontoON Canada;
Section of Medical Oncology and HematologyUniversity of TorontoON Canada;
Section of Medical Oncology and HematologyUniversity of TorontoON Canada;
Section of Medical Oncology and HematologyUniversity of TorontoON Canada;
Section of Medical Oncology and HematologyUniversity of TorontoON Canada;
Section of Medical Oncology and HematologyUniversity of TorontoON Canada;
Section of Medical Oncology and HematologyUniversity of TorontoON Canada;
bone marrow transplantation; stem cell biology; transplantation;
机译:CD34 +细胞剂量对强度调理方案造血干细胞移植降低的影响
机译:CD34阳性细胞剂量对外周血干细胞同种异体移植后的结果的影响,其采用基于ATG的强度调理方案制备
机译:低剂量辐照和体内T细胞耗损对使用氟氮胺碱的减少强度调节对非恶性疾病的造血干细胞移植的影响
机译:Fludarabine phospete和Melphalan - 一种免疫抑制性降低的强度调理(RIC)治疗患者血液学恶性肿瘤患者的促孕酮干细胞移植方案
机译:免疫抑制剂用于造血干细胞移植的调理方案
机译:低强度调理方案前小剂量脾脏照射对老年骨髓纤维化患者造血干细胞移植的实用性
机译:CD34 +细胞剂量和第100天的完全供体嵌合与在血液系统恶性肿瘤异基因造血干细胞移植(HSCT)之前接受氟达拉滨/美法仑降低强度调节(RIC)的患者的存活率相关